

Roberta A Diotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6153610/publications.pdf>

Version: 2024-02-01

35
papers

1,013
citations

471061

17
h-index

433756

31
g-index

39
all docs

39
docs citations

39
times ranked

1902
citing authors

#	ARTICLE	IF	CITATIONS
1	Conventional and nontraditional delivery methods and routes of vaccine administration. , 2022, , 329-355.		0
2	Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in COVID-19. Journal of Thrombosis and Haemostasis, 2022, 20, 434-448.	1.9	50
3	Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2. Viruses, 2022, 14, 1232.	1.5	2
4	Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects. Journal of Medical Virology, 2021, 93, 2160-2167.	2.5	52
5	Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials. Emerging Microbes and Infections, 2021, 10, 206-209.	3.0	74
6	Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy. Viruses, 2021, 13, 1514.	1.5	12
7	Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection. PLoS Pathogens, 2021, 17, e1009878.	2.1	52
8	New Insights into Immune-Based Diagnosis, Therapy and Prophylaxis for Infectious Diseases 2020. Journal of Immunology Research, 2021, 2021, 1-2.	0.9	0
9	Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols. Virology Journal, 2020, 17, 103.	1.4	4
10	Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro. Frontiers in Microbiology, 2020, 11, 1704.	1.5	18
11	Editorial: Immunotherapeutic and Immunoprophylactic Strategies for Infectious Diseases. Frontiers in Immunology, 2020, 11, 1670.	2.2	3
12	Interferon-Î2-1a Inhibition of Severe Acute Respiratory Syndromeâ€“Coronavirus 2 In Vitro When Administered After Virus Infection. Journal of Infectious Diseases, 2020, 222, 722-725.	1.9	61
13	Next Generation Vaccines for Infectious Diseases. Journal of Immunology Research, 2019, 2019, 1-2.	0.9	11
14	Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines. Journal of Immunology Research, 2019, 2019, 1-13.	0.9	72
15	Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects. Journal of Virology, 2019, 93, .	1.5	21
16	Autoimmune hepatitis and occult HCV infection: A prospective single-centre clinical study. Autoimmunity Reviews, 2017, 16, 323-325.	2.5	6
17	Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge. Antiviral Research, 2017, 143, 48-61.	1.9	9
18	A Biologically-validated HCV E1E2 Heterodimer Structural Model. Scientific Reports, 2017, 7, 214.	1.6	32

#	ARTICLE	IF	CITATIONS
19	New Insights for Immune-Based Diagnosis and Therapy for Infectious Diseases. <i>Journal of Immunology Research</i> , 2017, 2017, 1-2.	0.9	1
20	Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab. <i>Viruses</i> , 2016, 8, 128.	1.5	2
21	Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. <i>Gut</i> , 2016, 65, 512-523.	6.1	67
22	Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy. <i>Antiviral Research</i> , 2014, 108, 94-103.	1.9	13
23	JC Polyomavirus (JCV) and Monoclonal Antibodies: Friends or Potential Foes?. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-11.	3.3	16
24	Peptide-Based Vaccinology: Experimental and Computational Approaches to Target Hypervariable Viruses through the Fine Characterization of Protective Epitopes Recognized by Monoclonal Antibodies and the Identification of T-Cell-Activating Peptides. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-12.	3.3	26
25	HCV Proteins and Immunoglobulin Variable Gene (IgV) Subfamilies in HCV-Induced Type II Mixed Cryoglobulinemia: A Concurrent Pathogenetic Role. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-11.	3.3	15
26	Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference. <i>Antiviral Research</i> , 2012, 96, 82-89.	1.9	27
27	Neutralization Interfering Antibodies: A Novel Example of Humoral Immune Dysfunction Facilitating Viral Escape?. <i>Viruses</i> , 2012, 4, 1731-1752.	1.5	26
28	A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments. <i>New Microbiologica</i> , 2012, 35, 289-94.	0.1	20
29	New therapeutic options for HCV infection in the monoclonal antibody era. <i>New Microbiologica</i> , 2012, 35, 387-97.	0.1	15
30	Neutralization activity and kinetics of two broad-range human monoclonal IgG1 derived from recombinant Fab fragments and directed against Hepatitis C virus E2 glycoprotein. <i>New Microbiologica</i> , 2012, 35, 475-9.	0.1	8
31	Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). <i>Virology</i> , 2010, 399, 144-152.	1.1	40
32	Hepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral Genotypes. <i>PLoS ONE</i> , 2009, 4, e8254.	1.1	64
33	Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV). <i>New Microbiologica</i> , 2009, 32, 319-24.	0.1	22
34	Hepatitis C virus (HCV)-driven stimulation of subfamily-restricted natural IgM antibodies in mixed cryoglobulinemia. <i>Autoimmunity Reviews</i> , 2008, 7, 468-472.	2.5	33
35	Identification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 Protein. <i>Journal of Virology</i> , 2008, 82, 1047-1052.	1.5	119